[1]陈 赟,周雨欣,王 伟,等.毓麟珠联合地诺孕素治疗卵巢子宫内膜异位囊肿疗效及对患者卵巢功能的影响[J].陕西中医,2023,(1):29-32.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.007]
　CHEN Yun,ZHOU Yuxin,WANG Wei,et al.Clinicalefficacy of Yulinzhu combined with dienogest in the treatment of ovarian endometrioma and its effect on ovarian function[J].,2023,(1):29-32.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.007]
点击复制

毓麟珠联合地诺孕素治疗卵巢子宫内膜异位囊肿疗效及对患者卵巢功能的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年1期
页码:
29-32
栏目:
临床研究
出版日期:
2023-01-05

文章信息/Info

Title:
Clinicalefficacy of Yulinzhu combined with dienogest in the treatment of ovarian endometrioma and its effect on ovarian function
作者:
陈 赟1; 周雨欣2; 王 伟1; 李健美1; 卢 苏1
(1.南京中医药大学附属医院,江苏 南京 210029; 2.南京中医药大学,江苏 南京 210029)
Author(s):
CHEN Yun; ZHOU Yuxin; WANG Wei; LI Jianmei; LU Su
(Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China)
关键词:
卵巢子宫内膜异位囊肿;  毓麟珠;  地诺孕素;  卵巢功能;  糖类抗原125;  糖类抗原199
Keywords:
Ovarian endometriosis cyst;  Yulinzhu;  dienogest;  Ovarian function;  Carbohydrate antigen 125;  Carbohydrate antigen 199
分类号:
R 711.74
DOI:
DOI:10.3969/j.issn.1000-7369.2023.01.007
文献标志码:
A
摘要:
目的:探究毓麟珠联合地诺孕素治疗卵巢子宫内膜异位囊肿临床疗效及对患者卵巢功能的影响。方法:选取60例卵巢子宫内膜异位囊肿患者,按随机法分成对照组(n=30)和试验组(n=30),两组均给予地诺孕素片治疗,在此基础上,给予试验组患者毓麟珠联合治疗6个月,比较两组患者的临床疗效、肿瘤标记物、停药后的卵泡发育、1年后妊娠率、不良反应情况。结果:试验组患者的临床治疗总有效率明显高于对照组(P<0.05); 治疗前,两组患者的肿瘤糖类抗原125(CA125)及糖类抗原199(CA199)指标比较差异均无统计学意义(P>0.05); 用药6个月,试验组妇科肿瘤指标CA125低于对照组(P<0.05),两组CA199比较差异无统计学意义(P>0.05); 停药时,两组患者的卵泡发育比例比较差异无统计学意义(P>0.05); 停药3个月备孕期,两组患者的卵泡发育占比均提升,且试验组高于对照组(P<0.05); 1年后,试验组患者的妊娠率高于对照组(P<0.05),而不良反应发生率低于对照组(P<0.05)。结论:给予卵巢子宫内膜异位囊肿患者毓麟珠联合地诺孕素治疗可有效增强患者临床疗效,改善其卵巢功能,提高生育能力具有重要作用,并降低不良反应。
Abstract:
Objective:To investigate the clinical efficacy of Yulinzhu combined with dienogest in the treatment of ovarian endometriosis cyst and its influence on ovarian function.Methods:60 patients with ovarian endometriosis cyst were randomly divided into the control group(n=30)and the test group(n=30)according to the sorting method.Both groups were treated with dienogest tablets.On this basis,the patients in the test group were treated with Yulinzhu combination therapy.The clinical efficacy,tumor markers,follicular development after drug withdrawl,pregnancy rate after one year,and adverse reactions of the two groups were compared.Results:The effective rate of clinical treatment in the test group was significantly higher than that in the control group(P<0.05); Before treatment,the indexes of tumor carbohydrate antigen 125(CA125)and carbohydrate antigen 199(CA199)in the two groups had no significant difference(P>0.05).After 6 months of treatment,the gynecological tumor index CA125 in the treatment group was lower than that in the control group(P<0.05),and the difference of CA199 was not statistically significant(P>0.05); When the treatment was stopped,there was no significant difference between the two groups in the proportion of follicular development(P>0.05).The proportion of follicular development in the two groups increased after the treatment was stopped for 3 months in preparation for pregnancy,and the test group was higher than the control group(P<0.05).One year later,the pregnancy rate in the test group was higher than that in the control group(P<0.05),while the incidence of adverse reactions was lower than that in the control group(P<0.05).Conclusion:The combination of Yulinzhu and dienogest can effectively enhance the clinical efficacy of patients with ovarian endometriosis cyst,improve their ovarian function,reduce adverse reactions improve fertility.

参考文献/References:

[1] 郎景和.对子宫内膜异位症认识的历史、现状与发展[J].中国实用妇科与产科杂志,2020,36(3):193-196.
[2] 冷金花.子宫内膜异位症诊治指南(第三版)[J].中华妇产科杂志,2021,12(56):812-824.
[3] 纪 晓,王 飞,姜晓媛,等.地诺孕素联合中药治疗子宫内膜异位症的疗效及其对妊娠、复发的影响[J].中国医师进修杂志,2020,4(10):930-934.
[4] 莫小余.毓麟珠汤加减治疗卵巢储备不足的临床分析[J].中国现代药物应用,2019,13(23):2-5.
[5] 宁艳春,王婧瑶,赵铭佳,等.卵巢子宫内膜异位症患者卵泡液炎症因子水平和卵丘颗粒细胞的变化及其与体外受精-胚胎移植结局的关系[J].中国医药,2018,13(6):910-913.
[6] 中国中西医结合学会妇产科专业委员会.子宫内膜异位症中西医结合诊治指南[J].中国中西医结合杂志,2019,39(10):1169-1176.
[7] Kim HJ,Lee HS,Kazmi SZ,et al.Familial risk for endometriosis and its interaction with smoking,age at menarche and body mass index:A population based cohort study among siblings[J].BJOG:An International Journal of Obstetrics & Gynaecology,2021,128(12):1938-1948.
[8] 陈小飞,王贵娥.单孔悬吊式腹腔镜手术结合GnRh-α对卵巢子宫内膜异位囊肿患者AMH及HMGB1与RBP4的影响[J].当代医学,2019,25(33):42-44.
[9] 王新香,张朝红.血清性激素和胰岛素水平对子宫内膜异位症合并不孕症的预测价值[J].陕西医学杂志,2021,50(1):41-43.
[10] Marcellin L,Santulli P,Bourdon M,et al.Serum antimüllerian hormone concentration increases with ovarian endometrioma size[J].Fertil Steril,2019,111(5):944-952.
[11] 张玉虹,梁登辉,孙喜斌,等.地诺孕素治疗子宫内膜异位症的机制分析[J].陕西医学杂志,2015,44(4):400-402.
[12] 刘晓娟,贺 英,张玉虹,等.地诺孕素治疗子宫内膜异位症的机制探讨[J].陕西医学杂志,2014,43(6):646-647,697.
[13] 王 曼,陈 龙.桂莪棱乌汤联合地诺孕素治疗子宫内膜异位症的疗效及对血清CA125水平的影响[J].现代中西医结合杂志,2019,28(20):2244-2230.
[14] 黄裕平,柯琪文,范蕾蕾,等.地诺孕素治疗子宫内膜异位症的研究进展[J].临床医学研究与实践,2020,5(7):196-198.
[15] Lee SR,Yi KW,Song JY,et al.Efficacy and safety of long term use of dienogest in women with ovarian endometrioma[J].Reprod Sci,2018,25(3):341-346.
[16] 郭红玉,任青玲,胡荣魁,等.国医大师夏桂成辨治子宫内膜异位症不孕症经验[J].时珍国医国药,2022,33(5):1208-1210.
[17] 王 伟,李 瑾,谈 勇,等.夏桂成辨治子宫内膜异位症特色探析[J].安徽中医药大学学报,2018,37(6):44-45.
[18] 胡荣魁,谈 勇.夏桂成国医大师调治子宫内膜异位症经验探赜[J].江苏中医药,2015,47(7):1-4.
[19] 楼雪莉,陈 瑜.毓麟珠合桂枝茯苓丸加味治疗多囊卵巢综合征排卵障碍性不孕临床研究[J].新中医,2019,51(11):259-261.
[20] 艾贝贝,窦 娜.毓麟珠汤加减治疗肾阴虚型卵巢储备不足的临床疗效分析[J].中国性科学,2022,31(3):366-367.
[21] 李善霞,邓丽敏,谭青月,等.应用毓麟珠“从气论治”肾虚型早发性卵巢功能不全的临床观察[J].辽宁中医杂志,2021,48(8):116-119.
[22] 何文丽.毓麟珠汤加减治疗肾虚血瘀型多囊卵巢综合征54例[J].浙江中医杂志,2020,55(4):266-267.
[23] 王 璐,黄晓桃.脐灸联合毓麟珠改善促排卵周期中薄型子宫内膜临床研究[J].陕西中医,2019,40(8):1059-1062.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金青年基金资助项目(81904236); 江苏省妇幼健康青年人才项目(FRC202150)
更新日期/Last Update: 2022-12-28